Rising number of FDA approvals are driving the growth in Global Anti-Viral Drugs Market in the forecast period, 2022-2026.
According to TechSci Research report, “Global Anti-Viral Drugs Market By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, m-RNA Synthesis Inhibitors, Integrase Inhibitors, Others) By Indication (Coronavirus Infection, HIV, Hepatitis, Herpes Simplex Virus, Influenza, Others (Pneumonia, Flu)) By Route of Administration (Oral, Topical, Parenteral, Others) By Type (Branded, Generic) By Age Group (Pediatric, Adult, Geriatric) By End-User (Hospitals, Homecare, Specialty Clinics, Others) By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) By Region, Competition Forecast & Opportunities, 2026”, the global antiviral drugs market is projected to grow at an impressive CAGR in the forecast period, 2022-2026. The market attributes responsible for the growth of the market are increasing instances of research and development for the antiviral drugs and therapeutics. Moreover, the financial aid from the government and the private funding is supporting the research for the latest and advanced antiviral drugs and therapeutics with is driving the growth of the global antiviral rugs market in the next five years. Furthermore, FDA approvals for the various antiviral drugs and therapeutics have instigated the growth of the global antiviral drugs market. Infectious diseases like HIV, Hepatitis, Corona, etc. are spreading rapidly. Geriatric population, along with the young adults and kids are being affected due to various reasons. Geriatric population is catching infections because of their weak immune system and being susceptible to the infection, whereas the young adults are suffering due to poor lifestyle and busy schedules.
Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on “ Global Antiviral Drugs Market”
https://www.techsciresearch.com/report/anti-viral-drugs-market/7550.html
The global antiviral drugs market is segmented by drug class, indications, route of administration, type, age group, end users, distribution channel, competitional landscape, and regional distribution. Based on indications, the market is further bifurcated into coronavirus infection, HIV, hepatitis, herpes simplex virus, influenza, and others like pneumonia, flu, etc. Coronavirus infection is anticipated to register the fastest growing CAGR growth in the next five years, due to the recent outbreak. Although coronavirus variant has always been in the knowledge and often causes minor cold and fever, the new variant COVID-19 has proven to be deadly virus. World Health Organization (WHO) announced the viral infection spread to be a pandemic. It has already claimed millions of lives and continues to do so in various parts of South Asian countries like India, China, etc. HIV, Human Immunodeficiency Viruses are also major cause of viral infection. The drugs and therapeutics for the HIV patients are rapidly devised and produced due to increasing number of HIV positive patient. The viral infection attacks the immune system of the patient and renders them defenseless in the face of other infection which may cause ultimate death. The indication is anticipated to hold a significant revenue shares of the market segment. Whereas, Hepatitis A, B, C, and E, are most prevalent. By the year, 2019 the diseases held the largest segment of the market. Wide availability of antiviral drugs to treat hepatitis such as Entecavir, Tenofovir, Lamivudine, Telbivudine, and Adefovir can be attributed to its dominance over the market in the upcoming five years too.
Holding the largest revenue shares of the global antiviral drugs market, a partial list of the market player includes Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., GlaxoSmithKline PLC, Mylan N.V., Cipla Ltd., Laurus Labs Ltd., Micro Labs Ltd., Gilead Sciences, Inc., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Alembic Pharmaceuticals Limited, Novartis AG, Bristol Myers Squibb Company, AstraZeneca Ltd., among others. The market players are actively involved in the research and development of the antiviral drugs and therapeutics. With the advanced research, the pharmaceutical labs are able to counter act the viral infections that are widely spreading. Moreover, the ever changing environment and tendency of viral antigens to overcome the drugs and therapeutics effect, demand aggressive and consistent research for the advanced and effective drugs. New market players can adopt the very research for their market establishment. Other strategic recommendation may include partnerships and acquisitions.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7550
Customers can also request for 10% free customization on this report.
“North America region is anticipated to be the largest market ground for the antiviral drugs in the upcoming five years. With the advanced technology, consistent research and advanced healthcare industry the market is anticipated to grow multiple folds. Moreover, the region supports some of the largest economies like United States and Canada that has abundance of the market players with an established market. This factor is also responsible for the market growth to be exponential in the particular region. Whereas increasing the patient pool, improving the economic stability, and the presence of a strong and established generic drug market in the Asia Pacific region is making the region a potential market in the future five years,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based Global management consulting firm.
“Global Anti-Viral Drugs Market By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, m-RNA Synthesis Inhibitors, Integrase Inhibitors, Others) By Indication (Coronavirus Infection, HIV, Hepatitis, Herpes Simplex Virus, Influenza, Others (Pneumonia, Flu)) By Route of Administration (Oral, Topical, Parenteral, Others) By Type (Branded, Generic) By Age Group (Pediatric, Adult, Geriatric) By End-User (Hospitals, Homecare, Specialty Clinics, Others) By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) By Region, Competition Forecast & Opportunities, 2026”, has evaluated the future growth potential of global antiviral drugs and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global antiviral drugs market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]